Buprenorphine implant - Titan Pharmaceuticals

Drug Profile

Buprenorphine implant - Titan Pharmaceuticals

Alternative Names: Buprenorphine implant; Probuphine

Latest Information Update: 05 Jul 2017

Price : $50

At a glance

  • Originator Titan Pharmaceuticals
  • Developer Braeburn Pharmaceuticals; Knight Therapeutics; Titan Pharmaceuticals
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Opioid abuse
  • Phase I Pain

Most Recent Events

  • 13 Jun 2017 Preregistration for Opioid abuse in Canada (SC)
  • 16 Mar 2017 The EMA confirms that buprenorphine implant is eligible for review and centralised approval procedure in European Union
  • 16 Mar 2017 Titan Pharmaceuticals announces intention to submit MAA to the EMA for Opioid abuse in the fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top